Patient-reported outcomes in a phase III study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Receptors, Vascular Endothelial Growth Factor
  • Sirolimus

abstract

  • There was no evidence of a difference between everolimus and placebo in longitudinal patterns of disease-related symptoms, and little difference between the arms in physical functioning or global quality of life trends. This supports the conclusion that delay in tumor progression demonstrated by everolimus is associated with minimal impact on symptoms, physical functioning, or quality of life, as reported by patients.

publication date

  • May 25, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3228193

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.2010-0299

PubMed ID

  • 21459902

Additional Document Info

start page

  • 632

end page

  • 40

volume

  • 16

number

  • 5